Patients who stayed on their 1st TKI had a better chance of achieving CCyR and MMR1,2,*
Staying on a 1st TKI for 3 years vs switching between 6 months and 3 years was a strong predictor of achieving CCyR and MMR1,2*
*Based on European data from the SIMPLICITY study, an observational study of patients (N=370) newly diagnosed with Ph+ CML-CP who were followed for at least 3 years.1
OS rates in patients who stayed on their 1st TKI3
Many patients with CML discontinue their 1st TKI within 1 year5
In a retrospective study of 2043 patients with CML taking a 1st TKI5:
Limitations5
Administrative claims databases include diagnosis/procedure codes and prescription fills that are recorded for reimbursement purposes; claims may be subject to coding errors or data omissions
Given that TKI use was identified based on pharmacy claims for prescriptions filled, the actual consumption of the medication by the patient cannot be evaluated, and the exact timing of treatment modifications cannot be precisely estimated
Reasons for treatment modifications are not available
Some days may be fine, but other days may be miserable. It can feel like it's impossible for me to make plans.
–Actual CML patient
Get a perspective from CML experts and patients
CML, chronic myeloid leukemia; CCyR, complete cytogenetic response; MMR, major molecular response; OS, overall survival; Ph+ CML-CP, Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase; TKI, tyrosine kinase inhibitor.
References: 1. Gambacorti-Passerini C, Chen C, Davis C, et al. Eur J Haematol. 2021;106(1):82-89. 2. Goldberg SL, Cortes JE, Gambacorti-Passerini C, et al. Am J Hematol. 2017;92:1214–1223. 3. Mauro M, Paquette R, Hehlmann R, et al. Blood. 2022;140(suppl 1):9624-9625. 4. Hong JH, Winton EF, Heffner LT, et al. J Clin Med. 2020;9(5):1542-1553. 5. Kota V, Wei D, Yang D, et al, Poster presentation at: 65th ASH Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA.